Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.76 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | DRD5 | P21918 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598893 | 1.00 | ESR2 (0.76) | ESR2NR1H2ESR1NPC1RAB9A | |
| SCHEMBL3702146 | 0.95 | ESR2 (0.85) | ESR2NR1H2ESR1NPC1RAB9A | |
| SCHEMBL29372093 | 0.92 | ESR2 (0.90) | ESR2NR1H2ESR1NPC1RAB9A | |
| SCHEMBL545619 | 0.92 | ESR2 (0.90) | ESR2NR1H2ESR1NPC1RAB9A | |
| SCHEMBL29590844 | 0.86 | ESR2 (1.00) | ESR2NR1H2ESR1NPC1RAB9A | |
| SCHEMBL450677 | 0.86 | ESR2 (1.00) | ESR2NR1H2ESR1NPC1RAB9A | |
| SCHEMBL1168098 | 0.86 | ESR2 (0.79) | ESR2NR1H2ESR1MAPK1ABHD6 | |
| SCHEMBL24265586 | 0.86 | NR1H2 (0.62) | ESR2NR1H2NPC1RAB9AMAPK1 | |
| SCHEMBL1649493 | 0.86 | NR1H2 (0.62) | ESR2NR1H2NPC1RAB9AMAPK1 | |
| SCHEMBL29574152 | 0.86 | NR1H2 (0.62) | ESR2NR1H2NPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-05-17 | — | — | US | disclosed |
| EP-3728248-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-02-02 | — | — | EP | disclosed |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-17 | — | — | US | disclosed |
| US-20110172416-A1 | AMIDINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2311810-A1 | AMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2011-04-20 | — | — | EP | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| EP-1070714-A9 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-10-19 | — | — | EP | disclosed |
| EP-1070714-B1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-20040006099-A1 | Amidine compounds | JAPAN TOBACCO INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030158177-A1 | Treating or preventing obesity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| US-6562828-B1 | Novel amidine compound having a blood coagulation factor Xa inhibitory activity | JAPAN TOBACCO INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1283199-A1 | MELANIN-CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | ROCK1, ROCK2, RHOA | ESR2 3924/4885NR1H2 1964/4885ESR1 4483/4885 |
| US-20040006099-A1 | Amidine compounds | F2, SERPINC1, F12 | ESR2 3064/4885NR1H2 507/4885ESR1 3745/4885 |
| US-20030158177-A1 | Treating or preventing obesity | MCHR1, MC1R, NPY1R | ESR2 797/4885NR1H2 234/4885ESR1 1689/4885 |
| US-20110172416-A1 | AMIDINE DERIVATIVE | SERPINC1, F12, F11 | ESR2 4507/4885NR1H2 2374/4885ESR1 4690/4885 |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ESR2 3924/4885NR1H2 1964/4885ESR1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.